Jennerex and Green Cross sign S Korean development and sales accord for JX-594
USA-based Jennerex Biotherapeutics has signed an agreement with South Korean company Green Cross for its local development and commercialization of JX-594, Jennerex' oncolytic vaccinia virus for the treatment of liver cancer, as the initial indication. Under the terms of the deal, Green Cross will fund all development, regulatory, manufacturing and commercialization activities in its home market of South Korea and will pay a royalty on commercial sales, while Jennerex will supply JX-594 for the clinic though Green Cross will have options to manufacture JX-594 for the local market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze